These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
5. Successful management of pregnancy occurring in a patient with chronic myeloid leukemia on dasatinib. Kroll T; Ames MB; Pruett JA; Fenske TS Leuk Lymphoma; 2010 Sep; 51(9):1751-3. PubMed ID: 20629520 [No Abstract] [Full Text] [Related]
6. Dasatinib: a tyrosine kinase inhibitor for the treatment of chronic myelogenous leukemia and philadelphia chromosome-positive acute lymphoblastic leukemia. Steinberg M Clin Ther; 2007 Nov; 29(11):2289-308. PubMed ID: 18158072 [TBL] [Abstract][Full Text] [Related]
7. The daunting task of modeling response to imatinib therapy in patients with chronic myelogenous leukemia. Quintás-Cardama A; Kantarjian H; Cortes J Leuk Lymphoma; 2007 Apr; 48(4):802-4. PubMed ID: 17454640 [No Abstract] [Full Text] [Related]
8. Isolated central nervous system relapse in patient with blast-crisis chronic myeloid leukemia in durable complete cytogenetic remission on dasatinib treatment: pharmacokinetics and ABL mutation analysis in cerebrospinal fluid. Zhou HS; Dai M; Wei Y; Wang Q; Xu N; Yin C; Meng F Leuk Lymphoma; 2013 Jul; 54(7):1557-9. PubMed ID: 23194002 [No Abstract] [Full Text] [Related]
9. Isodicentric duplication of Philadelphia chromosome as a mechanism of resistance to dasatinib in a patient with chronic myeloid leukemia after resistance to imatinib. Loglisci G; Breccia M; Nanni M; Mancini M; De Cuia R; Cannella L; Salaroli A; Federico V; Serrao A; Loglisci MG; Santopietro M; Alimena G Leuk Lymphoma; 2011 Jul; 52(7):1372-5. PubMed ID: 21463110 [No Abstract] [Full Text] [Related]
10. Dasatinib-responsive chronic lymphocytic leukemia in a patient treated for coexisting chronic myeloid leukemia. Nagao T; Takahashi N; Kameoka Y; Noguchi S; Shinohara Y; Ohyagi H; Kume M; Sawada K Intern Med; 2013; 52(22):2567-71. PubMed ID: 24240798 [TBL] [Abstract][Full Text] [Related]
11. Severe adverse events associated with the use of second-line BCR/ABL tyrosine kinase inhibitors: preferential occurrence in patients with comorbidities. Valent P Haematologica; 2011 Oct; 96(10):1395-7. PubMed ID: 21972208 [No Abstract] [Full Text] [Related]
12. American Society of Hematology annual meeting. Fricker J Lancet Oncol; 2008 Jan; 9(1):13. PubMed ID: 18183660 [No Abstract] [Full Text] [Related]
13. New drugs: paliperidone, dasatinib, and decitabine. Hussar DA J Am Pharm Assoc (2003); 2007; 47(2):298-302. PubMed ID: 17510013 [No Abstract] [Full Text] [Related]
14. Dasatinib-induced response in a rare case of chronic lymphocytic leukaemia associated with chronic myeloid leukaemia. Tecchio C; Nichele I; Todeschini G; Pizzolo G; Ambrosetti A Br J Haematol; 2009 Jul; 146(2):222-3. PubMed ID: 19466973 [No Abstract] [Full Text] [Related]
15. [Pregnancy outcome among patients with chronic myelogenous leukemia treated with tyrosine kinase inhibitors]. Jiang Q; Jiang B; Chen SS; Jiang H; Qin YZ; Lai YY; Shi HX; Huang XJ Zhonghua Xue Ye Xue Za Zhi; 2012 Jan; 33(1):6-9. PubMed ID: 22575184 [TBL] [Abstract][Full Text] [Related]
16. Presence or the emergence of a F317L BCR-ABL mutation may be associated with resistance to dasatinib in Philadelphia chromosome-positive leukemia. Soverini S; Martinelli G; Colarossi S; Gnani A; Castagnetti F; Rosti G; Bosi C; Paolini S; Rondoni M; Piccaluga PP; Palandri F; Giannoulia P; Marzocchi G; Luatti S; Testoni N; Iacobucci I; Cilloni D; Saglio G; Baccarani M J Clin Oncol; 2006 Nov; 24(33):e51-2. PubMed ID: 17114651 [No Abstract] [Full Text] [Related]
18. Dasatinib may overcome the negative prognostic impact of KIR2DS1 in newly diagnosed patients with chronic myeloid leukemia. Ali S; Sergeant R; O'Brien SG; Foroni L; Hedgley C; Gerrard G; Milojkovic D; Stringaris K; Khoder A; Alsuliman A; Gilleece M; Gabriel IH; Cooper N; Goldman JM; Apperley JF; Clark RE; Marin D; Rezvani K Blood; 2012 Jul; 120(3):697-8. PubMed ID: 22822001 [No Abstract] [Full Text] [Related]
19. Pharmacoeconomic benefits of dasatinib in the treatment of imatinib-resistant patients with chronic myelogenous leukemia. Taylor MJ; Scuffham PA Expert Rev Pharmacoecon Outcomes Res; 2009 Apr; 9(2):117-21. PubMed ID: 19402798 [TBL] [Abstract][Full Text] [Related]
20. A T315I mutation in e19a2 BCR/ABL1 chronic myeloid leukemia responding to dasatinib. Cea M; Cirmena G; Garuti A; Rocco I; Palermo C; Cagnetta A; Moran E; Colombo N; Grasso R; Fugazza G; Gobbi M; Nencioni A; Ballestrero A; Patrone F Leuk Res; 2010 Sep; 34(9):e240-2. PubMed ID: 20447687 [No Abstract] [Full Text] [Related] [Next] [New Search]